Eurasian Journal of Medicine and Oncology最新文献_第5页

Simultaneous Integrated Boost Plan Comparison between Volumetric Modulated Arc Therapy (VMAT) and Intensity Modulated Radiation Therapy (IMRT) for Prostate, Seminal vesicle and Lymph Node Irradiation 前列腺、精囊和淋巴结放射治疗中体积调制弧线治疗(VMAT)和强度调制放射治疗(IMRT)同步集成增强计划的比较

Eurasian Journal of Medicine and Oncology Pub Date : 2022-01-01 DOI: 10.14744/ejmo.2022.75665

I. Ariyo

{"title":"Simultaneous Integrated Boost Plan Comparison between Volumetric Modulated Arc Therapy (VMAT) and Intensity Modulated Radiation Therapy (IMRT) for Prostate, Seminal vesicle and Lymph Node Irradiation","authors":"I. Ariyo","doi":"10.14744/ejmo.2022.75665","DOIUrl":"https://doi.org/10.14744/ejmo.2022.75665","url":null,"abstract":"Objectives: We performed a planning study to evaluate the dosimetric differences between Volumetric Modulated Arc Therapy (VMAT) and Intensity Modulated Radiation Therapy (IMRT) using simultaneous Integrated Boost (SIB) for prostate cancer cases. Methods: 20 prostate cancer patients scheduled for SIB-VMAT treatment on the Halcyon TM 2.0 linear accelerator were recruited for this study and SIB-IMRT plans were generated for comparison purpose. The pelvic lymph nodes (PTV46), the seminal vesicle (PTV50), and the prostate (PTV60) were simultaneously treated to 46 Gy 50 Gy, and 60 Gy delivered in 20 fractions respectively. Results: SIB-VMAT was better due to its higher (1.41%) CI, lower (2.7%) HI, and lower (26%) GI than SIB-IMRT for PTV60. For PTV50, a higher (7.3%) CI, lower (48%) HI, and a lower (31.73%) GI for SIB-VMAT compared to SIB-IMRT. Also, for PTV46, a higher (9.4%) CI, lower (2.5%) HI, and a lower (16.4%) GI were achieved by SIB-VMAT compared to SIB-IMRT. Conclusion: Better conformal and slightly similar homogeneous dose distribution were noticed in SIB-VMAT plans compared to SIB-IMRT plans. However, SIB-IMRT provided better OARs sparing of the bladder and the femoral heads while SIB-VMAT had better sparing for rectum.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83347723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is Pregnancy Characteristic Associated with Ovarian Cancer? A Review of the Available Evidence 妊娠特征与卵巢癌有关吗?现有证据的回顾

Eurasian Journal of Medicine and Oncology Pub Date : 2022-01-01 DOI: 10.14744/ejmo.2022.14462

Z. Momenimovahed

{"title":"Is Pregnancy Characteristic Associated with Ovarian Cancer? A Review of the Available Evidence","authors":"Z. Momenimovahed","doi":"10.14744/ejmo.2022.14462","DOIUrl":"https://doi.org/10.14744/ejmo.2022.14462","url":null,"abstract":"Numerous epidemiological studies examining the etiology of ovarian cancer and the role of pregnancy related factors in ovarian cancer has been one of the topics of interest to many researchers. Various articles have only mentioned the link between some risk factors and ovarian cancer, but no study has addressed the various dimensions of this issue to this day. Therefore, due to the important position of ovarian cancer among gynecological cancers, this study was conducted to investigate the pregnancy-related risk factors for ovarian cancer. relationship characteristic cancer, a comprehensive search was car-ried out in English databases as; Medline, Web of Science Core Collection, and Scopus using ovarian cancer (or 'carcinoma of the ovary' or 'ovarian neoplasm' or 'ovarian tumor'), risk factor, pregnancy characteristic terms and a combination of these terms. Full-text, English language, and original articles were included in this study. In total, 35 articles were entered into the study. The relationship between pregnancy related factors and ovarian cancer were studied. Although there was a weak association between some factors such as preterm birth and the risk of ovarian cancer, only the strong protective effect of parity was seen in the articles. The results of this study did not show that pregnancy related factors increase the risk of ovarian cancer. In summary, the findings are inadequate regarding some risk factors such as gender of fetus, multiple pregnancy, placental and fetal weight, parity, miscarriage, preeclampsia, and gestational diabetes, and raised questions for future research. Abstract","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73877500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment Protocols and Outcomes of Intraoperative Radiotherapy for Brain Metastases: A Systematic Review 脑转移瘤术中放疗的治疗方案和疗效:一项系统综述

Eurasian Journal of Medicine and Oncology Pub Date : 2022-01-01 DOI: 10.14744/ejmo.2021.29249

J. S. Pascual

引用次数: 0

A Multi-Molecular Fusion to Detect Transcriptomic Signature in Tissue-Specific Cancer 多分子融合检测组织特异性癌症的转录组学特征

Eurasian Journal of Medicine and Oncology Pub Date : 2022-01-01 DOI: 10.14744/ejmo.2022.53376

Saurav Mallik

引用次数: 2

Sarcomatoid Chromophobe Renal Cell Carcinoma 肉瘤样嫌色肾细胞癌

Eurasian Journal of Medicine and Oncology Pub Date : 2022-01-01 DOI: 10.14744/ejmo.2022.75565

J. F. Val Bernal

引用次数: 1

A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic COVID-19大流行期间SARS-CoV-2感染肺癌患者患病率的meta分析

Eurasian Journal of Medicine and Oncology Pub Date : 2022-01-01 DOI: 10.14744/ejmo.2022.50535

mohsen gholi-nataj

{"title":"A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic","authors":"mohsen gholi-nataj","doi":"10.14744/ejmo.2022.50535","DOIUrl":"https://doi.org/10.14744/ejmo.2022.50535","url":null,"abstract":"Objectives: Cancer patients were found to be at higher risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experienced more adverse outcomes. The objective of this meta-analysis was to estimate the prevalence of lung cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic. Methods: A comprehensive search was carried out on PubMed, Web of Science, Scopus, MedRxiv, SciELO, SID, CNKI, and Wanfang databases to retrieve all relevant publications. All cross-sectional studies and consecutive case series on cancer patients with SARS-CoV-2 infection were selected. A total of 28 studies including 5400 infected cancer patients and 767 lung cancer patients with COVID-19 were included. Results: Combined data indicated that the prevalence of lung cancer patients with SARS-CoV-2 infection was 15.2% (95% CI, 0.111–0.205) overall. Stratified analysis by ethnicity showed that the prevalence was 16.4% and 15.4% in Asian and Caucasian lung cancer patients with COVID-19, respectively. Moreover, subgroup analysis by country of origin showed that the prevalence was highest in China (19.3.0%) followed by France (12.6%), the UK (10.7%), and the USA (8.3%). Conclusion: This meta-analysis revealed that the prevalence of lung cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic was 15.2%. © 2022 by Eurasian Journal of Medicine and Oncology.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"605 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77498143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Development of Cancer in Gall Bladder Polyps Detected on Ultrasound in a High Risk Population 超声在高危人群中检测胆囊息肉癌的发展

Eurasian Journal of Medicine and Oncology Pub Date : 2022-01-01 DOI: 10.14744/ejmo.2022.71721

Anam Khan

引用次数: 0

Association of MATN-3 and ADIPOQ Polymorphisms with Susceptibility to Knee Osteoarthritis MATN-3和ADIPOQ多态性与膝关节骨关节炎易感性的关系

Eurasian Journal of Medicine and Oncology Pub Date : 2022-01-01 DOI: 10.14744/ejmo.2021.23898

A. Hashemzehi

引用次数: 1

Development of predictive in silico cytotoxic activity model to predict the cytotoxicity of a diverse set of colchicine binding site inhibitors 开发预测的硅细胞毒性活性模型，以预测多种秋水仙碱结合位点抑制剂的细胞毒性

Eurasian Journal of Medicine and Oncology Pub Date : 2022-01-01 DOI: 10.14744/ejmo.2022.44123

K. Ojha

引用次数: 2

Lenvatinib With or Without Immune Checkpoint Inhibitors in Subsets of Advanced Hepatocellular Carcinoma Lenvatinib联合或不联合免疫检查点抑制剂治疗晚期肝细胞癌亚群

Eurasian Journal of Medicine and Oncology Pub Date : 2022-01-01 DOI: 10.14744/ejmo.2022.25618

Yuxian Teng

{"title":"Lenvatinib With or Without Immune Checkpoint Inhibitors in Subsets of Advanced Hepatocellular Carcinoma","authors":"Yuxian Teng","doi":"10.14744/ejmo.2022.25618","DOIUrl":"https://doi.org/10.14744/ejmo.2022.25618","url":null,"abstract":"Objectives: Targeted agents combined with immune checkpoint inhibitors (ICIs) for advanced hepatocellular carcinoma (HCC) may improve survival for some patients. This study aims to identify the patients who are most likely to benefit from combination therapy. Methods: The study included 45 patients receiving lenvatinib while other 65 patients receiving lenvatinib plus ICIs between January 2019 and August 2020. Clinical and laboratory data were evaluated and compared. Results: The median follow-up was 20.5 months in the lenvatinib and 18.0 months in the combination group. The cor-responding median overall survival was 9.3 and 13.0 months (p=0.004), respectively. Subgroup analyses found that lenvatinib plus ICIs was associated with better overall survival in patients younger than 60 years, males, without MAFLD as well as with BMI <23 kg/m 2 , cirrhosis, HBV infection, total tumor volume ≥982 cm3, tumor burden score of ≥10.4 or α-fetoprotein ≥200 ng/ml. Conclusion: Lenvatinib plus ICIs therapy seems to be more effective in advanced HCC patients with viral etiology, low BMI, or high tumor load. Abstract With or Without Immune Checkpoint Inhibitors in Subsets of Advanced Hepatocellular Carcinoma.","PeriodicalId":11831,"journal":{"name":"Eurasian Journal of Medicine and Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76127398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4